|
|
|
Insider
Information: |
Baker Bros. Advisors (gp) Llc |
Relationship: |
|
City: |
New York |
State: |
NY |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
16 |
|
Direct
Shares |
608,718 |
|
Indirect Shares
|
158,658,441 |
|
|
Direct
Value |
$43,029,120 |
|
|
Indirect Value
|
$12,788,968,670 |
|
|
Total
Shares |
159,267,159 |
|
|
Total
Value |
$12,831,997,790 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
1
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
1
|
|
|
|
Gain/Loss Ratio : |
0.0
|
-1.0
|
Percentage
Gain/Loss : |
0.0%
|
-75.6%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Genomic Health Inc |
GHDX |
Director, 10% Owner |
2013-07-01 |
0 |
2019-02-27 |
9,235,362 |
Premium* |
|
Acadia Pharmaceuticals Inc |
ACAD |
Director, 10% Owner |
2014-03-05 |
0 |
2016-04-01 |
41,897,946 |
Premium* |
|
Incyte Corp |
INCY |
Director, 10% Owner |
2021-05-14 |
559,963 |
2021-05-14 |
29,367,926 |
Premium* |
|
XOMA Corporation |
XOMA |
Director, 10% Owner |
2014-05-22 |
0 |
2014-05-22 |
518,849 |
Premium* |
|
Aceragen, Inc |
ACGN |
Director |
2014-07-01 |
0 |
2016-01-04 |
78,885 |
Premium* |
|
Synageva BioPharma Corp |
GEVA |
Director, 10% Owner |
2015-01-07 |
1,020 |
2015-01-07 |
11,877,394 |
Premium* |
|
Mirati Therapeutics, Inc. |
MRTX |
10% Owner |
2016-06-09 |
274 |
2016-06-09 |
30,003 |
Premium* |
|
Intellia Therapeutics, Inc. |
NTLA |
Former 10% owner |
2016-05-11 |
0 |
2016-05-11 |
976,214 |
Premium* |
|
Invitae Corp |
NVTA |
10% Owner |
2016-11-17 |
0 |
2016-11-17 |
6,554,039 |
Premium* |
|
Bellicum Pharmaceuticals, Inc |
BLCM |
10% Owner |
2017-03-24 |
0 |
2023-11-22 |
2,168,818 |
Premium* |
|
Seagen Inc |
SGEN |
Director, 10% Owner |
2023-05-31 |
46,557 |
2023-05-31 |
42,977,301 |
Premium* |
|
Neurogene |
NGNE |
Director, 10% Owner |
2023-10-05 |
904 |
2023-10-05 |
1,658,190 |
Premium* |
|
Entrada Therapeutics, Inc. |
TRDA |
10% Owner |
2022-05-16 |
0 |
2022-06-06 |
4,501,658 |
Premium* |
|
Atreca Inc |
BCEL |
Former 10% Owner |
2023-10-19 |
0 |
2023-10-19 |
2,971,128 |
Premium* |
|
Igm Biosciences, Inc. |
IGMS |
|
2023-12-13 |
0 |
2024-03-29 |
3,755,474 |
Premium* |
|
Vtv Therapeutics Inc. |
VTVT |
|
2024-03-05 |
0 |
2024-03-05 |
89,254 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
103 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 3 of 5
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
INCY |
Incyte Corp |
Director |
|
2016-09-30 |
4 |
A |
$94.29 |
$56,857 |
I/I |
603 |
533,720 |
0 |
- |
|
NVTA |
Invitae Corp |
10% Owner |
|
2016-11-17 |
4 |
B |
$6.00 |
$4,399,998 |
I/I |
733,333 |
6,480,668 |
1.5 |
- |
|
INCY |
Incyte Corp |
Director |
|
2017-02-17 |
4 |
A |
$0.00 |
$0 |
I/I |
10,610,782 |
767,095 |
0 |
- |
|
BLCM |
Bellicum Pharmaceuticals,... |
10% Owner |
|
2017-03-24 |
4 |
B |
$12.00 |
$1,999,992 |
I/I |
166,666 |
4,527,089 |
1.5 |
- |
|
GHDX |
Genomic Health Inc |
Director |
|
2018-04-01 |
4 |
A |
$31.29 |
$119,778 |
I/I |
3,828 |
339,585 |
0 |
- |
|
GHDX |
Genomic Health Inc |
Director |
|
2018-11-16 |
4 |
S |
$76.35 |
$6,699,000 |
I/I |
(87,395) |
10,672,645 |
0 |
- |
|
GHDX |
Genomic Health Inc |
Director |
|
2018-11-26 |
4 |
S |
$74.05 |
$2,947,113 |
I/I |
(39,675) |
10,639,954 |
0 |
- |
|
GHDX |
Genomic Health Inc |
Director |
|
2018-11-27 |
4 |
S |
$73.76 |
$10,269,089 |
I/I |
(138,610) |
10,525,744 |
0 |
- |
|
GHDX |
Genomic Health Inc |
Director |
|
2019-01-23 |
4 |
S |
$70.52 |
$2,651,092 |
I/I |
(37,512) |
9,272,021 |
0 |
- |
|
GHDX |
Genomic Health Inc |
Director |
|
2019-01-24 |
4 |
S |
$72.02 |
$5,718,588 |
I/I |
(79,403) |
9,206,595 |
0 |
- |
|
GHDX |
Genomic Health Inc |
Director |
|
2019-01-25 |
4 |
S |
$72.20 |
$6,636,648 |
I/I |
(91,916) |
9,130,859 |
0 |
- |
|
GHDX |
Genomic Health Inc |
Director |
|
2019-01-28 |
4 |
S |
$70.55 |
$3,302,980 |
I/I |
(46,477) |
9,092,565 |
0 |
- |
|
GHDX |
Genomic Health Inc |
Director |
|
2019-02-26 |
4 |
S |
$77.81 |
$675,614 |
I/I |
(8,650) |
9,093,689 |
0 |
- |
|
GHDX |
Genomic Health Inc |
Director |
|
2019-02-26 |
4 |
OE |
$17.59 |
$290,235 |
I/I |
16,500 |
9,100,815 |
0 |
- |
|
INCY |
Incyte Corp |
Director |
|
2019-02-26 |
4 |
OE |
$2.80 |
$112,000 |
I/I |
40,000 |
29,288,793 |
0 |
- |
|
GHDX |
Genomic Health Inc |
Director |
|
2019-02-27 |
4 |
S |
$76.20 |
$2,997,792 |
I/I |
(39,109) |
9,061,465 |
0 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2019-06-06 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,002,483) |
4,302,354 |
0 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2019-06-06 |
4 |
A |
$0.00 |
$0 |
D/D |
148,458 |
181,733 |
0 |
- |
|
NGNE |
Neurogene |
Director |
|
2019-12-20 |
4 |
B |
$8.40 |
$25,347,353 |
I/I |
3,017,542 |
12,872,664 |
2.1 |
- |
|
NGNE |
Neurogene |
Director |
|
2019-12-20 |
4 |
D |
$0.00 |
$0 |
I/I |
(10,925,481) |
3,107,331 |
0 |
- |
|
INCY |
Incyte Corp |
Director |
|
2021-05-14 |
4 |
OE |
$18.97 |
$758,800 |
I/I |
40,000 |
29,334,516 |
0 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2022-03-08 |
4 |
OE |
$20.06 |
$702,100 |
I/I |
35,000 |
42,965,004 |
0 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2022-05-13 |
4 |
A |
$0.00 |
$0 |
I/I |
3,006 |
42,966,507 |
0 |
- |
|
TRDA |
Entrada Therapeutics, Inc... |
10% Owner |
|
2022-05-16 |
4 |
B |
$5.83 |
$110,692 |
I/I |
19,000 |
4,374,493 |
1.5 |
- |
|
TRDA |
Entrada Therapeutics, Inc... |
10% Owner |
|
2022-05-17 |
4 |
B |
$6.13 |
$113,474 |
I/I |
18,511 |
4,390,994 |
1.5 |
- |
|
103 Records found
|
|
Page 3 of 5 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|